Tumor specific CD8+ T cells in patients with lung cancer and healthy individuals

Journal of B.U.ON.

Volumn 14, Issue SUPPL.1, 2009, Pages

  Karanikas, Vaios ^a   Germenis, A ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Cytolytic T lymphocytes; Immunotherapy; Lung cancer

Indexed keywords

CANCER VACCINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MELANOMA ANTIGEN 3; MUCIN 1; WT1 PROTEIN;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; HUMAN; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; NONHUMAN; PROGNOSIS; TUMOR IMMUNITY;

ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; REFERENCE VALUES; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 70350058526     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (38)

1. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24: 175-208.
2. Coulie PG, Karanikas V, Lurquin C et al. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev 2002; 188: 33-42. (Pubitemid 35398863)
3. Gordan JD, Vonderheide RH. Universal tumor antigens as targets for immunotherapy. Cytotherapy 2002; 4: 317-327.
4. Karanikas V, Hwang LA, Pearson J et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 1997; 100: 2783-2792. (Pubitemid 28007547)
5. Davis ID, Jefford M, Parente P, Cebon J. Rational approaches to human cancer immunotherapy. J Leukoc Biol 2003; 73: 3-29. (Pubitemid 36125672)
6. Keyomarsi K, Pardee AB. Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents. Prog Cell Cycle Res 2003; 5: 527-532.
7. Wang E, Worschech A, Marincola FM. The immunologic constant of rejection. Trends Immunol 2008; 29: 256-262.
8. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-915.
9. Germeau C, Ma W, Schiavetti F et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005; 201: 241-248. (Pubitemid 40189433)
10. Correale P, Cusi MG, Tsang KY et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 2005; 23: 8950-8958. (Pubitemid 46211480)
11. Mapara MY Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004; 22: 1136-1151.
12. Jager D, Jager E, Knuth A. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol 2001; 54: 669-674. (Pubitemid 32835411)
13. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997; 9: 684-693.
14. Van der Bruggen P, Zhang Y et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002; 188: 51-64. (Pubitemid 35398865)
15. Karanikas V, Colau D, Baurain JF et al. High frequency of CTL directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001; 61: 3718-3724. (Pubitemid 32694985)
16. Echchakir H, Mami-Chouaib F, Vergnon I et al. A point mutation in the α-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 2001; 61: 4078-4083. (Pubitemid 32720974)
17. Slingluff CL Jr, Cox AL, Stover JM Jr, Moore MM, Hunt DF, Engelhard VH. Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68. Cancer Res 1994; 54: 2731-2737.
18. Groeper C, Gambazzi F, Zajac P et al. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer 2007; 120: 337-343. (Pubitemid 44956843)
19. Yoshino I, Goedegebuure PS, Peoples GE et al. HER2/neuderived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 1994; 54: 3387-3390. (Pubitemid 24225955)
20. Tajima K, Ito Y, Demachi A et al. Interferon-gamma differentially regulates susceptibility of lung cancer cells to telomerase-specific cytotoxic T lymphocytes. Int J Cancer 2004; 110: 403-412. (Pubitemid 38649892)
21. Gomi S, Nakao M, Niiya F et al. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. J Immunol 1999; 163: 4994-5004. (Pubitemid 29501267)
22. Sugaya M, Takenoyama M, Osaki T et al. Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest 2002; 122: 282-288. (Pubitemid 34754175)
23. Hiraoka K, Miyamoto M, Cho Y et al. Concurrent infiltration by CD8 T cells and CD4 T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006; 94: 275-280. (Pubitemid 43151547)
24. Naito Y, Saito K, Shiiba K et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58: 3491-3494. (Pubitemid 28376536)
25. Johnson SK, Kerr KM, Chapman AD et al. Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 2000; 27: 27-35.
26. Sugaya M, Takenoyama M, Shigematsu Y et al. Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung. Int J Cancer 2007; 120: 1055-1062. (Pubitemid 46214305)
27. Mami-Chouaib F, Echchakir H, Dorothée G, Vergnon I, Chouaib S. Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen. Immunol Rev 2002; 188: 114-121. (Pubitemid 35398869)
28. Karanikas V, Soukou F, Kalala F et al. Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals. Clin Immunol 2008; 129: 230-240.
29. Karanikas V, Tsochas S, Boukas K et al. Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: Implications for immunotherapy. Cancer Biol Ther 2008; 7: 345-352. (Pubitemid 351847046)
30. + T cell lineage commitment. Nat Immunol 2005; 6: 793-809. (Pubitemid 40719192)
31. Palmer M, Parker J, Modi S et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small cell lung cancer. Clin Lung Cancer 2001; 3: 49-58. (Pubitemid 32904315)
32. Butts C, Murray N, Maksymiuk A et al. Randomized phase HB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005; 23: 6674-6681. (Pubitemid 46190262)
33. Atanackovic D, Altorki NK, Stockert E et al. Vaccine-induced CD4 T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004; 172: 3289-3296. (Pubitemid 38263721)
34. Vansteenkiste J, Zielinski M, Linder A et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25: 18S, 7554.
35. Brichard VG, Lejeune D. GSK's antigen-specific cancer immunotherapy programme: pilot results leading to phase III clinical development. Vaccine 2007; 25 (Suppl 2): B61-B71. (Pubitemid 47488551)
36. Oka Y, Tsuboi A, Taguchi T et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885-13890. (Pubitemid 39298502)
37. Salazar LG, Fikes J, Southwood S et al. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 2003; 9: 5559-5565. (Pubitemid 37499475)
38. Disis ML, Gooley TA, Rinn K et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002; 20: 2624-2632. (Pubitemid 34575634)